Rat-to-Human PBPK Model of U-47700: Unveiling Pharmacokinetic Risks of a Synthetic Opioid Through Interspecies Extrapolation

Rat-to-Human PBPK Model of U-47700: Unveiling Pharmacokinetic Risks of a Synthetic Opioid Through Interspecies Extrapolation

Publication: Toxicol Appl Pharmacol
Software: GastroPlus®
Division: PBPK

U-47700, a synthetic μ-opioid receptor agonist and emerging new psychoactive substance, poses critical public health risks due to its high abuse liability and fatal overdose potential.

From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets

From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets

Publication: Pharmaceuticals
Software: GastroPlus®
Division: PBPK

Candesartan cilexetil, a Biopharmaceutics Classification System (BCS) II prodrug, demonstrates compromised bioavailability attributable to its limited aqueous solubility coupled with P-glycoprotein (P-gp)-mediated efflux and hepatic first-pass metabolism, thereby introducing complexities in generic drug bioequivalence assessments.

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Publication: Crit Rev Toxicol
Software: GastroPlus®
Division: PBPK

Ultraviolet (UV) filters, the active ingredients in sunscreens, have been used for several decades to reduce the risk of acute and chronic damage to the skin from solar UV radiation, which can lead to skin cancer.

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Mode of Action Approach Supports a Lack of Carcinogenic Potential of Six Organic UV Filters

Publication: Crit Rev Toxicol
Software: GastroPlus®
Division: PBPK

Ultraviolet (UV) filters, the active ingredients in sunscreens, have been used for several decades to reduce the risk of acute and chronic damage to the skin from solar UV radiation, which can lead to skin cancer.

Anxiety Disorders, PTSD and OCD: Systematic Review of Approved Psychiatric Medications (2008–2024) and Pipeline Phase III Medications

Anxiety Disorders, PTSD and OCD: Systematic Review of Approved Psychiatric Medications (2008–2024) and Pipeline Phase III Medications

Publication: Drugs Context
Software: GastroPlus®
Division: PBPK

This systematic review examines psychiatric medications approved by the FDA for anxiety disorders, post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD) from 2008 to 2024 and describes the mechanism of action, indications for both labelled and off-label uses, evidence for efficacy, dosing and adverse effects for each medication.

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling and its Regulatory Utility to Support Oral Drug Product Development and Harmonization

Publication: Pharmaceutical Research
Software: GastroPlus®
Division: PBPK
Therapeutic Areas: PBPK

This report summarizes the proceedings of Session 1 of the one-day public workshop titled “Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development” hosted by the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on October 12, 2023.

High vs. Low Vancomycin Therapeutic Concentrations in Periprosthetic Joint Infection: A Retrospective Cohort Analysis

High vs. Low Vancomycin Therapeutic Concentrations in Periprosthetic Joint Infection: A Retrospective Cohort Analysis

Publication: Front Pharmacol
Software: GastroPlus®
Division: PBPK

Current guidelines recommend vancomycin concentrations of 10–20 μg/mL for most infections, with higher levels (15–20 μg/mL) suggested for severe cases.

PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations

PBPK Modeling to Support Bioavailability and Bioequivalence Assessment in Pediatric Populations

Publication: Pharm Res
Software: GastroPlus®
Division: PBPK

This report summarizes the proceedings for Session 3 of the one-day public workshop entitled “Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development” a jointly sponsored workshop by U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on October 12, 2023.

Unveiling the Phenolic Profiling of Moroccan Ferula communis L. Fruits: A Combination of In Silico and In Vivo Protective Effect Against Methotrexate-Induced Hepato-Renal Dysfunction

Unveiling the Phenolic Profiling of Moroccan Ferula communis L. Fruits: A Combination of In Silico and In Vivo Protective Effect Against Methotrexate-Induced Hepato-Renal Dysfunction

Publication: Journal of Food Biochemistry
Software: ADMET Predictor®
Division: Cheminformatics

Methotrexate (MTX) is associated with several side effects, including hepatic and renal toxicities, which limit its effectiveness as an anticancer medication.

RSM and AI Based Machine Learning for Quality by Design Development of Rivaroxaban Push-Pull Osmotic Tablets and its PBPK Modeling

RSM and AI Based Machine Learning for Quality by Design Development of Rivaroxaban Push-Pull Osmotic Tablets and its PBPK Modeling

Publication: Sci Rep
Software: GastroPlus®
Division: PBPK

The study is based on applying Artificial Neural Network (ANN) based machine learning and Response Surface Methodology (RSM) as simultaneous bivariate approaches in developing controlled-release rivaroxaban (RVX) osmotic tablets.

A Physiologically Based Pharmacokinetic Model of an Oral Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Adults

A Physiologically Based Pharmacokinetic Model of an Oral Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Adults

Authors: Chen X, Lin Z
Publication: J Clin Pharmacol
Software: GastroPlus®
Division: PBPK

This study presents the first physiologically based pharmacokinetic (PBPK) model for deucravacitinib, a novel oral selective tyrosine kinase 2 (TYK2) inhibitor approved for treating moderate-to-severe plaque psoriasis.

Breaking Barriers in PROTAC Design: Improving Solubility of USP7-Targeting Degraders

Breaking Barriers in PROTAC Design: Improving Solubility of USP7-Targeting Degraders

Publication: ChemRxiv
Software: ADMET Predictor®
Division: Cheminformatics

The development of von Hippel–Lindau (VHL) hijacking proteolysis-targeting chimeras (PROTACs) has been hindered by suboptimal physicochemical properties, including high total polar surface area (TPSA), high hydrogen bond donor (HBD) counts, and poor solubility.

Next Generation Risk Assessment of Hair Dye HC Yellow no. 13: Ensuring Protection from Liver Steatogenic Effects

Next Generation Risk Assessment of Hair Dye HC Yellow no. 13: Ensuring Protection from Liver Steatogenic Effects

Publication: Regul Toxicol Pharmacol
Software: GastroPlus®
Division: PBPK

This study employs animal-free Next Generation Risk Assessment (NGRA) principles to evaluate the safety of repeated dermal exposure to 2.5% (w/w) HC Yellow No. 13 (HCY13) hair dye.